ImmunityBio, Inc. Profile Avatar - Palmy Investing

ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulato…

Biotechnology
US, San Diego [HQ]

Cash Flow Statements

10 Sheets · Starting from 2023
In Million USD. Margins, Growth Rates In %
Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Operating Activities
Operating Cash Flow (OCF)
-5.00 -25.00 -38.00 -48.00 -63.00 -152.00 -171.00 -274.00 -337.00 -366.00
Operating Cash (Net)
-5.00 -25.00 -38.00 -48.00 -63.00 -152.00 -171.00 -274.00 -337.00 -366.00
Accounts Receivable
- - - - -1.00 - - - - - - - - - - - - - -
Accounts Payable
- - - - - - - - -1.00 1.00 2.00 -3.00 8.00 -6.00
Working Capital
- - - - - - - - - - - - - - - - - - - -
Investing Activities
Used Cash (Net)
- - -175.00 -113.00 99.00 57.00 18.00 -19.00 -84.00 27.00 -30.00
Capital Expenditure
- - -2.00 -6.00 -34.00 -13.00 -4.00 -1.00 -33.00 -99.00 -30.00
Purchases of Investments
- - -198.00 -272.00 -119.00 -95.00 -87.00 -91.00 -141.00 -34.00 -10.00
Sale/Maturity of Investment
- - 26.00 165.00 254.00 165.00 112.00 73.00 69.00 162.00 10.00
Property, Plant, Equipment (P&PE)
- - -2.00 -6.00 -34.00 -13.00 -4.00 -1.00 -33.00 -99.00 -30.00
Acquisitions (Net)
- - -1.00 - - - - - - - - - - 20.00 -1.00 - -
Other Investing Activities
- - -1.00 - - - - 35.00 -2.00 - - -51.00 105.00 - -
Financing Activities
Used Cash (Net)
-64.00 -317.00 -15.00 -34.00 - - -114.00 -150.00 -505.00 -233.00 -558.00
Debt Repayment
- - - - - - -19.00 - - -2.00 -3.00 -338.00 - - -451.00
Dividends Paid
- - - - - - - - - - - - - - - - - - - -
Common Stock
- - 329 17 16 - - 32 86 168 61 113
Other Financing Activities
64.00 -2.00 -1.00 -1.00 - - 91.00 73.00 1,017.00 174.00 899.00
Cash Balances
Begin of Period
- - 59.00 175.00 8.00 23.00 95.00 75.00 35.00 181.00 104.00
End of Period
59.00 175.00 8.00 23.00 16.00 75.00 35.00 181.00 104.00 265.00
Change
58.00 116.00 -167.00 15.00 -7.00 -19.00 -40.00 146.00 -76.00 160.00
Non-Cash Balances
Depreciation and Amortization
- - 1.00 3.00 5.00 9.00 14.00 12.00 14.00 18.00 18.00
Stock Based Compensation
- - - - - - - - - - 3.00 2.00 57.00 40.00 49.00
Other
-61.00 212.00 81.00 50.00 44.00 6.00 24.00 23.00 29.00 138.00
Highlighted metrics
Free Cash Flow (FCF)
-5.00 -27.00 -45.00 -83.00 -76.00 -156.00 -173.00 -307.00 -436.00 -397.00
Cash Conversion Cycle (CCC)
- - - - - - - - - - -20.00 749.00 - - 2,954.00 1,677.00
Invested Capital
- - - - - - - - - - - - - - - - - - - -
Other Operating Inflows/Outflows
End of IBRX's Analysis
CIK: 1326110 CUSIP: 45256X103 ISIN: US45256X1037 LEI: - UEI: -
Secondary Listings
IBRX has no secondary listings inside our databases.